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ABSTRACT 
Objective: To describe the strategies adopted by nurses for safe administration of a potentially dangerous 
drug in the intensive care unit. Method: This is an exploratory study literature which included articles about 
potentially dangerous drugs and medication errors in intensive care units published in the period 1998 to 
2009. Results: The study included 16 items that resulted in three categories of potentially dangerous 
medications (amines, heparin and insulin), which were described the light of error prevention strategies. 
Conclusion: The occurrence of adverse events with potentially dangerous medications is mostly 
preventable, and that for each class of potentially dangerous medications can be taken specific measures to 
prevent possible adverse events. Descriptors: Nursing care, Intensive care, Medication errors, Adverse drug 
reaction and security. 
 
RESUMO 
Objetivo: Descrever as estratégias adotadas pelo enfermeiro para uma administração segura de um 
medicamento potencialmente perigoso em unidade de terapia intensiva. Método: Trata-se de estudo 
exploratório bibliográfico onde foram incluídos artigos sobre medicamentos potencialmente perigosos e 
erros de medicação em unidades de terapia intensiva publicados no período de 1998 a 2009. Resultado: 
Foram analisados 16 artigos que resultaram em três categorias de medicamentos potencialmente perigosos 
(aminas, heparinas e insulinas), que foram descritas a luz das estratégias preventivas de erros. Conclusão: A 
ocorrência de eventos adversos com medicamentos potencialmente perigosos é na maioria das vezes, 
evitável, e que para cada classe de medicamentos potencialmente perigosos podem ser adotadas medidas 
específicas a fim prevenir possíveis eventos adversos. Descritores: Assistência de enfermagem, Cuidados 
intensivos, Erros de medicação, Reação adversa a medicamento e segurança. 
 
RESUMEN 
Objetivo: Describir las estrategias adoptadas por las enfermeras para la administración segura de una droga 
potencialmente peligrosa en la unidad de cuidados intensivos. Método: Se trata de una literatura estudio 
exploratorio que incluyó artículos acerca de las drogas potencialmente peligrosas y los errores de 
medicación en unidades de cuidados intensivos publicados en el período 1998 a 2009. Resultados: El estudio 
incluyó 16 artículos que dieron lugar a tres categorías de medicamentos potencialmente peligrosos (aminas, 
la heparina y la insulina), que fueron descritos a la luz de las estrategias de prevención de errores. 
Conclusión: la ocurrencia de eventos adversos con medicamentos potencialmente peligrosos es en su 
mayoría prevenibles, y que para cada clase de medicamentos potencialmente peligrosos se pueden tomar 
medidas específicas para prevenir posibles efectos adversos. Descriptores: Cuidados de enfermeira, 
Cuidados intensivos, Los errores de medicación, Reacciones adversas a medicamentos y seguridad. 
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The medications administration is one of 
the most commonly used interventions in the 
hospital environment, however, some studies have 
revealed the existence of mistakes during the drug 
therapy that can cause harm to patients, by 
ranging from the non-administration of such a 
drug until injuries and deaths caused by 
inadequate doses of such a drug, or when a drug is 
indicated to the wrong patient.1,2 
The erroneously administered medications 
are directly linked to the issue of patient safety. 
According to the World Health 
Organization, the term “patient safety” consists in 
“reducing the risk of unnecessary harms 
associated with the healthcare to an acceptable 
minimum level”, which has motivated discussions, 
since this care action is performed by human 
beings, hence, they are liable to make mistakes. 3 
Within this issue linked to the patient 
safety regarding the medications administration, it 
is understood by Adverse Event, “an incident that 
occurs to a patient and results in harm, arising 
from the care provided to it and not related to 
the natural progression of the underlying 
disease”.3 
By considering the survey of Harvard 
Medical Practice Study II, adverse events with the 
highest incidence are related to medication 
mistakes, being that most of them are considered 
avoidable. One can say that between 50% and 60% 
of adverse events are preventable.4,5 
It is estimated that, in the United States, 
the mistakes related to the drug therapy have 
reached about 1,3 million people per year, by 
generating a cost that, annually, reaches 76,6 
billion dollars related to patients’ admission due 
to adverse events.6 
Faced with the high incidence of mistakes 
related to the use of medicinal drugs, one must 
emphasize the requirement of an extensive 
technical/scientific knowledge by the nursing 
professional, as regards to the medications 
handling, since some medicinal drugs have 
singular capability of damaging the patient when 
mistakes are committed during their use. Such 
medications are called high-alert medications or 
high risk medications; here, in Brazil, they are 
called potentially dangerous medications, in 
compliance with the ANVISA nomenclature. 
The intensive care units are extremely 
vulnerable sites to adverse events occurrences, 
due to a higher probability of invasive procedures 
occurrence, multiple medications administration, 
severity of pathologies and the need for fast 
decision-making. One study reports that the 
prevalence of adverse event with potentially 
dangerous medications is settled in several sectors 
in the hospital environment, but there was a 
higher concentration in intensive care units.7 
Based on these considerations, we have 
drawn as the study object the establishment of 
some strategies for a safe administration of a 
potentially dangerous medication in intensive care 
unit environment and with the aim at describing 
the strategies adopted by the nursing professional 
for a safe administration of a potentially 
dangerous medication in intensive care unit scope. 
 
 
 
To meet the objective proposed in this 
study, we have performed an exploratory 
literature research with the following steps: 
research question, descriptors selection, selection 
criteria definition, bibliographic material survey, 
categories organization and data analysis. The 
study was grounded on the following guiding 
question: what strategies should be adopted by 
INTRODUCTION 
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the nursing professional for a safe administration 
of a potentially dangerous medication in the 
intensive care unit scope? 
The study object definition was conducted 
by including all papers on potentially dangerous 
medications and medication mistakes in intensive 
care units published in the period from 1998 to 
2009 and which were indexed in the following 
databases: Agência Nacional de Vigilância 
Sanitária (ANVISA), Virtual Health Library (VHL), 
Latin American and Caribbean Health Sciences 
(LILACS), World Health Organization (WHO), 
PUBMED, Scientific Electronic Library Online 
(SciELO) and the Inter-American Society of 
Pharmacovigilance (ISPhar), with a view to 
meeting the literature recommendation of seeking 
in different sources when performing a 
publications survey. The selection criteria were: 
articles in Portuguese and English with texts 
available in their full version in the established 
period, indexed by the following descriptor 
expressions: “Nursing care”; “Intensive care”; 
“Medication mistakes”; “Adverse reaction to 
medication” and “Safety”; besides making 
reference to the admitted adult population. For 
data collection, we have developed a tool based 
on literature review protocols, being that we 
replaced items originally written in English 
“citation” and “intervention” by “título” and 
“procedimentos metodológicos”.  
The 16 selected papers were divided into three 
categories (amines, heparins and insulins) that 
supported the analysis of the data obtained in this 
study. 
 
 
The survey was resulted of 54 different 
papers arranged in the selected databases, by 
adding review studies or original data 
presentation.  
The results emerged from selection of 16 
papers, relevant to the issue and the study object, 
which were analyzed and, subsequently, grouped 
into three medication categories: amines7,11,14, 
anticoagulants17,20,22,23  and insulins24,25,26,27,28,29,30, 
being that such a grouping guided the study 
discussion. The aforementioned categories were 
created from the reading of papers. 
It should be highlighted that the 
publication period of the articles analyzed in this 
research, which has formed an updating paper, 
was specifically established as a result of the 
availability of the scientific material that was 
found, by showing a gap between the 
technological and practical advances of the 
nursing staff in intensive care units and the 
publication thereof, by this same professional 
category, which hindered the development of our 
labor.  
Most of papers have highlighted legal and 
ethical issues inherent in the nursing profession, 
as well as the civil accountability of the nursing 
professional before of the potentially dangerous 
medications administration in the intensive care 
unit and its repercussions arising from avoidable 
adverse events, i.e., medication mistakes.  
Given the alarming statistics about the 
incidence of adverse events with potentially 
dangerous medications in the intensive care units, 
studies of Toffoleto and Padilha reveal that every 
eight patients/day, one patient suffers an adverse 
event. Another study also highlights that every 300 
patients/day, one fatal adverse event occurs; 
being that every 750 patients/day might be 
represented as one avoidable death for every 68 
weeks.8,9,10 
Before these discussions, the three 
medication classes covered in this study will be 
presented below by means of categories, in order 
to subsidize a technical and scientific foundation 
for the proposal of describing safe administration 
RESULTS AND DISCUSSION 
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strategies for potentially dangerous medications in 
intensive care unit scope. 
Category I: vasoactive medications (amines)7,11,14 
Amines are drugs that have their actions 
focused on the cardiac output regulation, which is 
the end product of the systolic volume versus the 
cardiac rate, where the systolic volume is related 
to the ventricular filling volume and pressures, 
also called pre-load, as well as the resistance to 
the myocardial emptying and contractility, called 
after-load. These are medications that, in small 
doses, produce fast responses, which can generate 
a dose-dependence effect.11. 
Thus, the main avoidable adverse events 
related to the amines are: cardiac arrhythmias, 
arterial hypotension/hypertension, 
bradycardia/tachycardia and urinary tract 
changing.12,13  
Faced with the severity of changes 
provoked in the body by the improper use of these 
medications, the incidence rates of 31% and the 
avoidable adverse events related to the 
administration thereof, which have already been 
mentioned in this paper, we suggest some 
extreme important strategies for the safe 
administration of this class of potentially 
dangerous medications, which will be hereinafter 
described.7 
According to the Norepinephrine label, the 
amines administration should strictly occur in 
continuous infusion pump and their dosage should 
be monitored through daily weight assessment, 
since it will enable the infusion of the correct 
dose in function of the patient's needs, by 
avoiding an overdosage and consequent 
tachycardia/ arterial hypertension. 12 
The amines administration should 
exclusively occur in deep venous catheter, in 
order to avoid disorders caused by accidental 
leakage of these medicinal drugs13, such as tissue 
necrosis adjacent to the catheter, due to the 
vesicant hydrogenionic potential (pH) of this 
medications class, i.e.,  pH below the normal 
plasma pH (7:35 -7:45). Given these 
considerations, one must be careful about the pHs 
of some medications, such as: Dobutamine (pH 2.5 
– 5.5) Epinephrine (pH - 2.2), Dopamine (pH = 2.5) 
and Norepinephrine (pH=4.5).14,15 
With regard once more to the vasoactive 
medications administration, it was observed that 
there is a convention in clinical practice regarding 
the use of deep venous catheters, where we 
should give preference to always insert these 
medicinal drugs through the proximal route (which 
should be identified to provide exclusivity) since 
this has a “prime” (gauge), gravitational flow and 
infusion rate (ml/hr) lower than the other lumen 
(distal and medial), with a view to avoiding 
“flushes” of these medications and, consequently, 
their overdosage.  
During amines infusion, there should be a 
frequent assessment of the peripheral tissue 
perfusion, through the verification of the 
peripheral pulses, since they might be associated 
to the risk of developing pressure ulcers by 
decreased peripheral perfusion in dosages from 2 
to 15 mcg/kg/min. Moreover, we should promote 
body warming (especially of the extremities) with 
quilts and/or blankets, bear in the mind the 
peripheral vasoconstriction caused by these 
medications.16 
Due to the increased systemic arterial 
resistance (in dosages from 2 to 15 mcg /kg/min) 
and considering the arrhythmogenic potential of 
amines, it should be installed the continuous 
cardiac monitoring, pulse oximetry and invasive 
method (or minimally invasive) for monitoring the 
blood pressure, with sights to accurately control 
the patient’s hemodynamic parameters in use of 
vasoactive medications.16 
According to the Norepinephrine label, in 
relation to the hemodynamic monitoring, the 
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measurement of vital signs should occur every 5 
minutes throughout the infusion, since the amines 
have dependent doses and that the endogenous 
release might alter the route of exogenous 
absorption. Nonetheless, it was practically 
observed that the vital signs can be hourly 
measured, without incurring in damages to the 
hemodynamic monitoring and the care itself, as 
well as the patient's condition.12 
In the hemodynamic monitoring, for 
performing a precise control of the urinary output, 
one should perform a permanent vesical 
catheterization and establishing a rigorous hydric 
balance, because these medications have peculiar 
action over the regulatory parameters of the 
cardiac output and the reduction of organ 
perfusion, given that some amines make use of 
the renal system like excretory route, which might 
interfere with the diuresis, being that it should be 
leveled between 0.5 and 1 ml/kg/h.13 
Through the above mentioned strategies, it 
can be inferred that the safe administration of 
amines should be performed in a systematic and 
extremely careful manner by the whole nursing 
staff, so that it contributes to the reduction of 
avoidable adverse events rates due to this 
medication class.  
Category II: anti-thrombotic (heparins)17, 20, 22, 23 
The antithrombotic drugs are widely used in 
several treatments in intensive care units, both in 
preventive and in therapeutic way. They 
encompass various medication types. But, we have 
decided to address only those most commonly 
used in intensive care units throughout this study, 
i.e., intravenous and subcutaneous heparins, 
which will be discussed in this category.17 
The intravenous heparin (also known as non-
fractionated heparin) acts through two 
anticoagulant mechanisms: direct inhibition of 
thrombin and factor Xa inhibition, thus interfering 
in the coagulation cascade. The drug therapy with 
intravenous heparinization is known as Raschke 
Scheme, which aims at maintaining serum levels 
of heparin between 0.35 and 0.70 U/ml, according 
to the patient’s body weight. This scheme 
provides for the initial heparin administration in 
bolus, by giving continuity to the therapy with 
permanent infusion under rigorous analysis of 
APTT (activated partial thromboplastin time) and 
PTT (partial thromboplastin time).17,18 
Thus, the main avoidable adverse events 
associated to the intravenous heparin are: 
bleeding /hemorrhages and thromboembolism (in 
case of insufficient doses). Before the risks and 
changes in the body caused by the improper use of 
this medicinal drug, as well as the incidence of 
avoidable adverse events related to the 
administration thereof, as previously mentioned, 
we suggest some crucial strategies for the safe 
administration of this class of potentially 
dangerous medications, which will be hereinafter 
mentioned.19 
According to the heparin protocol from the 
Albert Einstein Israelite Hospital, the non-
fractionated heparin administration should strictly 
occur in continuous infusion pump and its dosage 
should be adjusted by daily weight assessment, 
since it will enable the infusion of the correct 
dose in function of the patient's needs, in order to 
avoid an overdosage and consequent and, 
consequently, hemorrhagic events.17 
With regard once more to the non-
fractionated heparin administration, it was 
observed that there is a convention in the clinical 
practice with regard to the use of deep venous 
catheters, where one should give preference to 
always install this medication in the proximal 
route (which should be identified to provide 
exclusivity) since this has a “prime” (gauge), 
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gravitational flow and infusion rate (ml/hr) lower 
than the other lumen (distal and medial), with a 
iew to avoiding “flushes” of such a medication 
and, consequently, its overdosage.  
Another strategy to assure the safe 
administration is setting the therapeutic dose, 
which requires a rigorous collection and 
assessment of the activated partial thromboplastin 
time (APTT), initially every 6 hours, by increasing 
the time interval to control to every 12/12 hours, 
when the healthcare professional achieves two 
consecutive controls within the ideal range (61-85 
seconds).20  
Concerning the subcutaneous heparin (or 
low molecular weight heparin), also frequently 
used in intensive care, it is primarily metabolized 
in the liver, by causing depolymerization and/or 
desulfation, when forming molecules of lower 
weight, with extremely reduced biological 
potency, which results in a safe medication in its 
administration, with less risk of hemorrhages and 
thrombocytopenia. The drug therapy recommends 
the subcutaneous heparin administration at 
1mg/kg-2x/day and prophylactic subcutaneous 
heparin at 40mg 1x/day or, furthermore, 
intravenous heparin 5.000 IU through 
subcutaneous route for every 8/8 hours. It is 
worth mentioning that, according to the Food and 
Drug Administration (FDA), the use of 
subcutaneous heparin is not recommended for 
patients under hemodialysis treatment, since the 
primary excretion route is the renal one.17,21,22. 
Thus, the main avoidable adverse events 
related to the subcutaneous heparin are: 
bleeding/hemorrhage and necrosis of the 
subcutaneous tissue. According to the risks caused 
in the body by the inappropriate use of this 
medication, as well as the incidence of avoidable 
adverse events associated to the administration 
thereof, as previously mentioned, we suggest 
some crucial strategies for the safe administration 
of this class of potentially dangerous medications, 
which will be reported below.17 
It is worth mentioning that there is a small 
inert gas bubble into the syringe of subcutaneous 
heparin, which should not be removed, because its 
function is to avoid the medication leakage.23 
In line with the suggested strategies, one 
can say that the safe administration of heparins, 
both venous and subcutaneous should be 
performed in a standardized way, according to 
institutional protocols, in order to contribute to 
the preventable adverse events prevention in 
this medication category. 
Category III: insulin24-30 
It is an anabolic hormone that holds 
regulatory action of the glucose homeostasis in 
several levels, by reducing the hepatic glucose 
production (gluconeogenesis and glycogenolysis) 
and increasing the peripheral glucose uptake, 
especially, in muscle and adipose tissues. 
Moreover, it stimulates the lipogenesis in the 
liver and adipocytes and reduces the lipolysis, as 
well as increases the synthesis and inhibits the 
protein degradation.24 
Given the above, it worth mentioning that 
among patients admitted to the intensive care 
unit is common the existence of changes in the 
endocrine and metabolic system, whether with or 
without a previous diagnosis of diabetes mellitus. 
The elevated glucose levels are strongly 
associated with increased morbidity and mortality 
indexes in patients under intensive care. This is 
corroborated by a study conducted by Van den 
Berghe (2001) addressing critical patients in an 
intensive care unit, which showed that intensive 
control of blood glucose levels with continuous 
intravenous insulin therapy drastically reduced 
morbidity and mortality when compared to the 
subcutaneous therapy. 25 
The hyperglycemia in the intensive care 
patient is a constant factor related to the 
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response to the organic stress, where there is 
increased release of counterregulatory hormones 
secretion, by decreasing the insulin secretion and 
action and favoring the hyperglycemia and the 
peripheral insulin resistance. Added to this 
situation, one can see the common interventions 
in intensive care units, such as corticotherapy, 
therapy with vasoactive amines and nutritional 
supports, which culminates in the worsening of 
the patient's hyperglycemic state. 26 
Concerning the hypoglycemia, associated 
with the intravenous insulin therapy, occurs in 
about 4 to 7% of patients, by reflecting the result 
of the excessive insulin administration; insulin 
infusion maintenance without concomitant 
replacement of dextrose solution at 5%, after 
obtaining glucose ≤ 250 mg/dl; inability to 
interpret institutional protocols and difficulties of 
administering the dosage. 27 
Hence, to maintain the blood glucose in an 
acceptable range, it is recommended to 
implement an insulin therapy protocol with 
defined strategies, thus preventing complications 
such as hypoglycemia. That said, we recommend 
some strategies necessary for a safe 
administration of the single insulin type that can 
be intravenously administered (regular insulin), 
which will be hereinafter considered. 28 
The intravenous regular insulin 
administration should strictly occur in continuous 
infusion pump and its dosage should strictly be 
controlled, with sights to avoid hypoglycemia. 28 
According to Van den Berghe et al., during 
the whole time of regular intravenous insulin 
infusion, there should be an intensive monitoring 
of the glycemic control (hourly) and of the 
hypoglycemia signs such as: cold and clammy 
sweating, mucocutaneous paleness and altered 
awareness level, which are anticipated to this 
event that can harm the central nervous system, if 
it is not immediately identified and corrected.25 
Another important measure of monitoring 
consists in daily contrast the results of the 
capillary blood glucose with the results of the 
serum glucose, in order to detect very different 
values in the event of failure of the glucometer 
available at the healthcare unit, thus avoiding 
hypo or hyperglycemia intercurrences arising from 
wrong dosages. 28 
With regard to the glycemic monitoring, it 
is recommended to collect, preferably in a closed 
system of deep access, a minimal blood volume 
necessary for performing the capillary blood 
glucose, in order to avoid discomfort, pain 
resulting from multiple digit-punctures, infection 
risk linked to numerous invasive procedures, as 
well as contribute to the eradication of anemia 
caused by excessive collections of laboratory 
examinations.28 
To prevent severe hypoglycemia and its 
irreversible effects on the central nervous system, 
one should administer/ offer diet or some glucose 
intake (according to the route by clinical 
indication) immediately before the beginning of 
the intravenously regular insulin infusion. The 
same author states that one should suspend the 
administration concomitant with the interruption 
of enteral or parenteral infusion, before the 
hemodialysis time, (considering the hypoglycemic 
effects inherent in the therapeutic time), since it 
can trigger a severe hypoglycemia and its 
irreversible effects over the central nervous 
system, in case of non-interruption of the 
medicinal drug stream.29 
Concerning the leading preventable 
adverse events related to the regular insulins by 
subcutaneous administration route, they are 
hypoglycemia and necrosis of subcutaneous tissue, 
which characterize avoidable adverse events 
during the administration of these drugs, due to 
the misuse or ineffective monitoring throughout 
the therapy. Before the presented risks, we 
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propose some important strategies for the safe 
administration of this class of potentially 
dangerous medications, which will be hereinafter 
publicized.30 
According to Clayton, to prevent abscess 
and/or necrosis of subcutaneous tissue, pain at the 
injection site and promote a quick absorption of 
insulin by means of subcutaneous route, according 
to the application site, depending on the need of 
the absorption speed thereof in the body, one 
should implement and maintain the rotation of sites 
for applying thereof.16 
Furthermore, according to the 
aforementioned scholar, it should be performed a 
skinfold thickness by using only two fingers, in order 
to avoid the lifting of the muscular fascia, as well 
as the pain arising from this maneuver. Moreover, 
according to the already cited protocol, to avoid 
the lifting of the tissue trauma and changes in the 
drug absorption, after the insulins administration by 
means of subcutaneous route, it is recommended to 
apply a soft pressure on the administration site and 
do not rub it.16,17 
According to Van den Berghe, for 
anticipating in relation to the hypoglycemia, 
which can bring about harms to the central 
nervous system, if it is not immediately identified 
and corrected, it is recommended to coordinate 
the meal times with the use of subcutaneous 
insulin, besides monitoring the capillary glucose 
levels (pre-prandial ones) and the hypoglycemia 
signs such as: cold and clammy sweating, 
mucocutaneous paleness, as well as altered 
awareness level, during the administration of 
these medicinal drugs. 25 
Given the need for insulin therapy, it is a 
task of the nursing professional to show ability 
towards the protocol adopted in its institution, 
holding pathophysiological knowledge of 
hypo/hyperglycemia and establishing preventive 
strategies to deal with adverse events, in order to 
maintain adequate glycemic control and success in 
therapy, as the proposals of this study. 
 
 
 
This study highlights how the avoidable 
adverse events are common in the hospital 
environment, especially in intensive care units, 
due to the complexity of pathologies, 
technological advancement, as well as greater 
likelihood of invasive procedures, and that such 
incidents can occur in several times throughout 
the admission. It also emphasizes that the most 
frequent preventable adverse events are related 
to medications, especially, to the potentially 
dangerous medications, which can be fatal.  
We have confirmed that the nursing care 
provided in the intensive care unit is dedicated in 
a complex scope, composed of critical ill patients 
and modern technological methods, whose need 
requires a high level of professional qualification 
and structural resources that are appropriated to 
provide a careful attendance to the patient, 
where the recognition of adverse events and 
factors attached to them enables the 
identification of the weak points of this varied 
care process, as well as to implement 
interventions aimed at improving the care quality. 
In view of this, we conclude that, for 
achieving the reduction of avoidable adverse 
events in the potentially dangerous medications 
administration in intensive care units, it is 
necessary to simplify the care processes and 
standardize the administration system of each 
class of these medicinal drugs. Furthermore, the 
nurses should also propose prevention strategies 
for applying in these units, given their potential 
risk and wide-ranging use thereof, with sight to 
contribute to the care improvement and safety 
promotion for the patient who needs it. 
CONCLUSION 
 
ISSN 2175-5361                                                                                  DOI: 10.9789/2175-5361.2013v5n3p142  
                                                                                                                                                                                                                                                                                                         
Camerini FG, Silva LD, Gonçalves TG et al.                                                               Preventive strategies… 
                                                   
J. res.: fundam. care. online 2013. jul./set. 5(3):142-152 
 
150 
It should be noted the importance of 
conducting and publishing further surveys 
involving such an issue, since there were few 
Brazilian data obtained in this study on the 
occurrence of avoidable adverse events, which 
hampered the situational diagnosis of the reality 
experienced by Brazil, as well as the adopted 
measures to prevent avoidable adverse events 
related to the potentially dangerous medications 
administration in the intensive care unit scope. 
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